Protagonist Therapeutics, Inc (PTGX): EBITDA
-$156.85M
Year ended 2025-12-31
$59.88M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$156.85M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $253.67M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$92.67M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$130.34M | n/m | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | -$125.03M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$63.57M | n/m | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | -$79.79M | n/c | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$41.74M | n/m | 2021-03-10, From 2018-01-01 |
| 2017-12-31 | -$37.49M | n/m | 2020-03-10, From 2017-01-01 |
| 2016-12-31 | -$32.35M | n/m | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | -$14.55M | n/m | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | -$9.06M | n/a | 2017-03-07, From 2014-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | -$156.85M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | -$66.70M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$70.50M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $1.35M | n/m |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$40.44M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.70M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$48.29M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$11.21M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$265.69M | n/m |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗